This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ dibekacin

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Bacterial Infections: Dibekacin is effective against a wide range of bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter species. These infections can affect various parts of the body, including the respiratory tract, urinary tract, skin, soft tissues, and bloodstream.

  2. Respiratory Tract Infections: Dibekacin may be used to treat respiratory tract infections, including pneumonia, bronchitis, and bronchiectasis, particularly when caused by multidrug-resistant gram-negative bacteria.

  3. Urinary Tract Infections: Dibekacin can be effective in treating urinary tract infections (UTIs) caused by susceptible bacteria. This includes infections of the bladder (cystitis) and kidneys (pyelonephritis).

  4. Skin and Soft Tissue Infections: Dibekacin may be used to treat skin and soft tissue infections, including cellulitis, abscesses, and wound infections, particularly when caused by gram-negative bacteria.

  5. Bacterial Meningitis: In some cases, dibekacin may be used in the treatment of bacterial meningitis, particularly when caused by gram-negative bacteria. However, its use in meningitis may be limited due to concerns about penetration into the cerebrospinal fluid and potential neurotoxicity.

  6. Hospital-Acquired Infections: Dibekacin may be used to treat infections acquired in healthcare settings, including ventilator-associated pneumonia and bloodstream infections caused by multidrug-resistant bacteria.

  7. Otitis Externa: Dibekacin may be prescribed for the treatment of otitis externa (swimmer's ear) caused by susceptible bacteria.

  8. Eye Infections: Dibekacin ophthalmic solution may be used to treat bacterial eye infections, such as conjunctivitis (pink eye) and keratitis (corneal inflammation), caused by susceptible bacteria.

  9. Cystic Fibrosis: Dibekacin may be used as part of the treatment regimen for cystic fibrosis patients who have chronic respiratory infections caused by multidrug-resistant gram-negative bacteria.

  10. Precautions and Side Effects: Like other aminoglycoside antibiotics, dibekacin carries a risk of side effects, including nephrotoxicity (kidney damage), ototoxicity (hearing loss or vestibular dysfunction), and neuromuscular blockade. Therefore, it is important to monitor patients closely for signs of toxicity, especially when using high doses or prolonged treatment durations.

  11. Resistance: Overuse or inappropriate use of dibekacin can contribute to the development of antibiotic resistance. Therefore, it should be used judiciously and in accordance with local antimicrobial resistance patterns and guidelines.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of dibekacin On Probiotics

Bacteria Impacted by dibekacin

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

Impact of dibekacin on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]